Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01475149 · ClinicalTrials.gov registry record

Effect of HCQ on AnxA5 Resistance Assay in Antiphospholipid (aPL) Positive Patients With and Without Systemic Lupus Erythematosus (SLE)

A clinical trial, sponsored by Hospital for Special Surgery, New York.

Completed
Registry status
33
Enrollment target

NCT01475149 is a clinical trial that has completed, run by Hospital for Special Surgery, New York. The registered enrollment target is 33 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01475149 has completed, sponsored by Hospital for Special Surgery, New York.

COMPLETED
Registry status
33 participants
Enrollment target

Study Summary

This 12 week study will observe patients with and without systemic lupus erythematosus who have persistent antiphospholipid antibodies in the blood who are starting a medicine called hydroxychloroquine. It will measure if these patients have a change in a blood test called the annexin A5 resistance assay over that 12 week period.

Interventions

  • OTHER Phlebotomy

Trial Details

FieldValue
Enrollment Target 33 participants
Start Date 2010-09
Est. Completion 2016-08

What the Registry Record Tells You About NCT01475149

The ClinicalTrials.gov registry entry for NCT01475149 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hospital for Special Surgery, New York, which has 194 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Phlebotomy is the first listed.

NCT01475149 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01475149 about?

NCT01475149 is a clinical study titled "Effect of HCQ on AnxA5 Resistance Assay in Antiphospholipid (aPL) Positive Patients With and Without Systemic Lupus Erythematosus (SLE)". This 12 week study will observe patients with and without systemic lupus erythematosus who have persistent antiphospholipid antibodies in the blood who are starting a medicine called hydroxychloroquine. It will measure if these patients have a change in a blood test called the annexin A5 resistance ...

What is the current status of trial NCT01475149?

This trial is currently completed. The enrollment target is 33 participants. The study started on 2010-09. Estimated completion is 2016-08.

What interventions are being tested in trial NCT01475149?

The interventions under investigation include: Phlebotomy (OTHER).

Who is sponsoring clinical trial NCT01475149?

This trial is sponsored by Hospital for Special Surgery, New York, which has 194 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.